Clinical Trials Directory

We are doing this study to find out if an experimental therapy called CB-011 (the study drug) is a safe and effective option for people who have relapsed or refractory multiple myeloma.

We are doing this study to monitor the health and quality of life of people who participated in clinical trials for GM T cell therapies.

We are doing this study to find out if an experimental drug called CC-92480 (the study drug) is a safe and effective treatment for multiple myeloma. We also want to figure out the most appropriate dose and schedule for giving the study drug to multiple myeloma patients.

We are doing this study to find out if an experimental drug called cema-cel is a safe and effective option for patients with large B-cell lymphoma. Cema-cel is a CAR T Cell therapy that is made from your own white blood cells. We also want to compare how well cema-cel works when it is given with and without another experimental drug called ALLO-647.

We are doing this study to learn if a combination of chemotherapies and immunotherapies (carboplatin, cabazitaxel, nivolumab and ipilimumab) slows cancer growth in patients with metastatic neuroendocrine or aggressive variant prostate cancer. We also want to learn about the types of side effects that patients have while they are taking these study drugs together.

We are doing this study to find out if an experimental drug called mosunetuzumab (the study drug) is a safe and effective option for patients with follicular lymphoma.

We are doing this study to find out if neratinib combined with palbociclib is better than neratinib alone when it comes to treating HER2-positive tumors.

We are doing this study to learn how to best support young women making decisions about breast cancer surgery. We want to know what makes women feel uncertain about their decision-making so we can become better at providing the information they need. This study involves testing a web-based decision support tool that is designed to help young women with newly diagnosed breast cancer with their surgical decisions.